This article is more than 5 years old. Information may no longer be current.

Monoclonal antibodies provide ‘huge step forward’ in treating multiple myeloma

Issue: August 10, 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The editors of HemOnc Today have compiled an interactive online supplement that provides the most recent research available on patients with multiple myeloma.

In the supplement, key opinion leaders share their insights on the CASTOR trial, which demonstrated the addition of daratumumab to bortezomib and dexamethasone significantly prolonged PFS among patients with relapsed or refractory disease.

Results from a phase 3 trial that demonstrated upfront autologous hematopoietic stem cell transplantation prolonged PFS compared with bortezomib-containing chemotherapy, are included, along with a perspective from Saad Z. Usmani, MD, FACP, a HemOnc Today Editorial Board member.

The supplement also reviews how FDA approvals of carfilzomib, elotuzumab, ixazomib and panobinostat will bring about new therapeutic decision challenges. 

Click here to view the interactive pdf, and visit Healio.com/HemOnc for daily updates and breaking news in the specialty.